Engineered oncolytic virus OH2-FLT3L enhances antitumor immunity via dendritic cell activation

Area of Science:

• Oncology
• Virology
• Immunology

Background:

• Combining oncolytic viruses (OVs) with immunotherapies is a key research area.
• Optimizing OV therapeutic potential requires further investigation.
• Novel strategies are needed to enhance OV-mediated antitumor immune responses.

Purpose of the Study:

• To design and evaluate a novel oncolytic herpes simplex virus 2 expressing Fms-like tyrosine kinase 3 ligand (OH2-FLT3L).
• To assess OH2-FLT3L's ability to induce antitumor cytotoxic T cell responses via dendritic cell (DC) activation.
• To investigate the combination therapy of OH2-FLT3L with anti-PD-1 antibody.

Main Methods:

• Engineered OH2-FLT3L to express Fms-like tyrosine kinase 3 ligand.
• Assessed OH2-FLT3L's tumor cell infectivity and induction of immunogenic cell death (ICD).
• Evaluated DC activation, T cell response, tumor microenvironment changes, and therapeutic efficacy in vivo.

Main Results:

• OH2-FLT3L specifically infected tumor cells, induced ICD, and released tumor antigens.
• OH2-FLT3L facilitated DC cross-presentation, enhancing T cell activation and function.
• OH2-FLT3L increased activated DCs, boosted antitumor immunity, and converted "cold" to "hot" tumors.
• Combination with anti-PD-1 antibody further improved therapeutic outcomes.

Conclusions:

• OH2-FLT3L is a novel oncolytic virus with potential for enhancing antitumor immunity.
• DC activation is a key mechanism by which OH2-FLT3L exerts its effects.
• OH2-FLT3L holds promise for improving cancer immunotherapy, particularly in combination strategies.